$0.52
1.48% day before yesterday
Nasdaq, Aug 22, 10:19 pm CET
ISIN
US00534A1025
Symbol
IVVD

Adagio Therapeutics Inc Stock price

$0.52
-0.24 31.57% 1M
-0.72 58.06% 6M
+0.08 17.38% YTD
-0.36 40.77% 1Y
-3.65 87.53% 3Y
-16.48 96.94% 5Y
-16.48 96.94% 10Y
-16.48 96.94% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
-0.01 1.48%
ISIN
US00534A1025
Symbol
IVVD
Industry

Key metrics

Basic
Market capitalization
$62.5m
Enterprise Value
$14.4m
Net debt
positive
Cash
$48.1m
Shares outstanding
120.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.7 | 0.6
EV/Sales
0.4 | 0.1
EV/FCF
negative
P/B
1.2
Financial Health
Equity Ratio
52.2%
Return on Equity
-251.6%
ROCE
-272.8%
ROIC
-315.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$36.7m | $113.0m
EBITDA
$-144.4m | $-22.5m
EBIT
$-147.7m | $1.0m
Net Income
$-142.7m | $-5.3m
Free Cash Flow
$-141.6m
Growth (TTM | estimate)
Revenue
- | 345.2%
EBITDA
34.2% | 87.0%
EBIT
33.0% | 100.6%
Net Income
31.0% | 96.9%
Free Cash Flow
22.4%
Margin (TTM | estimate)
Gross
93.3%
EBITDA
-393.5% | -20.0%
EBIT
-402.6%
Net
-389.0% | -4.7%
Free Cash Flow
-385.8%
More
EPS
$-1.2
FCF per Share
$-1.2
Short interest
4.7%
Employees
100
Rev per Employee
$250.0k
Show more

Is Adagio Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Adagio Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Adagio Therapeutics Inc forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Adagio Therapeutics Inc forecast:

Buy
78%
Hold
22%

Financial data from Adagio Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
37 37
-
100%
- Direct Costs 2.45 2.45
-
7%
34 34
-
93%
- Selling and Administrative Expenses 65 65
23% 23%
178%
- Research and Development Expense 117 117
30% 30%
318%
-144 -144
34% 34%
-394%
- Depreciation and Amortization 3.33 3.33
278% 278%
9%
EBIT (Operating Income) EBIT -148 -148
33% 33%
-403%
Net Profit -143 -143
31% 31%
-389%

In millions USD.

Don't miss a Thing! We will send you all news about Adagio Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adagio Therapeutics Inc Stock News

Neutral
GlobeNewsWire
2 days ago
WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the closing of its previously announced underwritten public offering of 89,234,480 shares of its common stock, which includes the exercise in full by the underwriter of its option to purchase an additional 14,423,076 shares of common stock, at a public offering price of $0.52 per share and p...
Neutral
GlobeNewsWire
4 days ago
WALTHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 74,811,404 shares of its common stock at an offering price of $0.52 per share and, to certain investors, in lieu of common stock, pre-funded warrants to purchase 21,342,442 shares of its common stock at a price of $0.5199 per pre-funded warrant.
Neutral
GlobeNewsWire
4 days ago
WALTHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the shares of Invivyd common stock sold in the public offering at the public of...
More Adagio Therapeutics Inc News

Company Profile

Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren? Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Head office United States
CEO William Duke
Employees 100
Founded 2020
Website invivyd.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today